BRAF突变与结直肠癌特异性生存的关联取决于微卫星状态和肿瘤分期
该回顾性分析纳入德国22家医院1995例结直肠癌患者(2003–2010年),按微卫星状态和BRAF突变分四类,中位随访5.1年。结果显示,微卫星稳定(MSS)且BRAF突变患者的总体生存(HR 2.16)、疾病特异性生存(HR 2.59)和无复发生存(HR 2.45)均显著差于MSS无BRAF突变者;在MSS肿瘤中,BRAF突变与III或IV期患者疾病特异性生存相关(P < .001),但不影响II期患者生存(P = .639)。
要点
- MSS且BRAF突变患者的总生存、疾病特异性生存和无复发生存均显著差于MSS无BRAF突变者。
- 在MSS肿瘤中,BRAF突变与III或IV期患者疾病特异性生存相关(P < .001),但不影响II期患者(P = .639)。
- 在MSI-H患者中,BRAF突变未显著影响生存时间。
核心结论
- 在近2000例结直肠癌患者分析中,BRAF突变降低MSS的III或IV期(而非II期)患者的生存。
- 这些发现不支持对I或II期结直肠肿瘤进行BRAF突变检测,尽管需要进一步的大型研究。
研究设计与样本
- 回顾性分析1995例结直肠癌肿瘤样本,来自德国22家医院,收集于2003年至2010年。
- 采用已建立的单核苷酸标记物组分析MSI-H;BRAF突变(BRAFV600E)通过Sanger测序或组织微阵列块的免疫组化检测。
- 肿瘤分为四类:MSS无BRAF突变、MSS伴BRAF突变、MSI-H无BRAF突变、MSI-H伴BRAF突变。
- 中位随访时间为5.1年。
主要发现
- 肿瘤分期:I期364例(18%),II期678例(34%),III期673例(34%),IV期280例(14%)。
- 肿瘤位置:结肠63%,直肠37%。
- 肿瘤分类:MSS无BRAF突变85%,MSS伴BRAF突变3%,MSI-H无BRAF突变7%,MSI-H伴BRAF突变5%。
- 在MSI-H患者中,BRAF突变未显著影响生存时间。
- MSS伴BRAF突变患者较MSS无BRAF突变患者:总生存HR 2.16(95%CI 1.54-3.04,P < .001),疾病特异性生存HR 2.59(95%CI 1.77-3.79,P < .001),无复发生存HR 2.45(95%CI 1.70-3.52,P < .001)。
临床怎么用
- 作者认为,这些发现不支持对I或II期结直肠肿瘤进行BRAF突变检测,尽管需要进一步的大型研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Colorectal tumors with mutations in BRAF and microsatellite stability (MSS) have been associated with adverse outcomes of patients. Combined tests for microsatellite instability-high (MSI-H) and BRAF mutations might therefore be used in risk assessment, particularly for patients with stage II tumors. We investigate the stage-specific prognostic value of combined testing for MSI-H and BRAF for patients with colorectal cancer. METHODS: We performed a retrospective analysis of colorectal tumor samples collected from 1995 patients at 22 hospitals in Germany, between 2003 and 2010. Samples were analyzed for MSI-H using an established mononucleotide marker panel; BRAF mutations (BRAFV600E) were detected by Sanger sequencing or in tissue microarray blocks using immunohistochemistry. Cancers were assigned to categories of having MSS without mutations in BRAF, MSS with mutant BRAF, MSI-H without mutations in BRAF, and MSI-H with mutant BRAF. We investigated the association between tumor categories with clinical and pathologic features and patient's overall, disease-specific, and recurrence-free survival (median follow-up time, 5.1 y). RESULTS: Tumors were stage I in 364 (18%), stage II in 678 (34%), stage III in 673 (34%), and stage IV (14%) in 280 patients. Sixty-three percent of tumors were located in the colon and 37% in the rectum. Most tumors (85%) had MSS without mutations in BRAF, 3% had MSS with mutant BRAF, 7% had MSI-H without mutations in BRAF, and 5% had MSI-H with mutant BRAF. In patients whose tumors were MSI-H, mutation of BRAF did not significantly affect survival time. Patients whose tumors had MSS with mutant BRAF had significantly reduced overall survival (hazard ratio [HR], 2.16; 95% CI, 1.54-3.04; P < .001), disease-specific survival (HR, 2.59; 95% CI, 1.77-3.79; P < .001), and recurrence-free survival (HR, 2.45; 95% CI, 1.70-3.52; P < .001) than patients whose tumors had MSS without BRAF mutation. Although BRAF mutations in tumors with MSS were associated with disease-specific survival of patients with stage III or IV tumors (P < .001), these features did not affect survival of patients with stage II tumors (P = .639). CONCLUSIONS: In an analysis of almost 2000 patients with colorectal cancer, we found BRAF mutations to reduce survival of patients in stage III or IV (but not stage II) tumors with MSS. These findings do not support testing stage I or II colorectal tumors for BRAF mutations, although additional large studies are needed.
引用
- Bläker H, Alwers E, Arnold A, et al. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. Clin Gastroenterol Hepatol. 2018. PMID: 29660527. doi:10.1016/j.cgh.2018.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。